The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

European Journal of Health Economics

Volumn 11, Issue 6, 2010, Pages 585-594

  Willis, Michael ^a   Svensson, Marianne ^a   Löthgren, Mickael ^b   Eriksson, Bo ^b   Berntsson, Anders ^c   Persson, Ulf ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b Janssen Cilag   (Sweden)

^c Psychiatry North East ^*  (Sweden)

Author keywords

Health resources; Mirror image study design; Risperidone; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CONFIDENCE INTERVALS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INPATIENTS; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; SWEDEN; TIME FACTORS;

EID: 78649903563     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0215-9     Document Type: Article

References (10)

1. DA Regier WE Narrow DS Rae RW Manderscheid BZ Locke FK Goodwin 1993 The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services Arch. Gen. Psychiatry 50 85 94
2. O Niaz P Haddad 2007 Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Acta Psychiatr. Scand. 116 36 46 10.1111/j.1600-0447.2006.00980.x (Pubitemid 46889775)
3. Fuller, M., Shermock, K., Secic, M., Engelhart, L., Vallow, S., Flanders, S.: Hospitalization and resource utilization in schizophrenia following initiation of risperidone long-acting injection in the Veterans Affairs Healthcare System (VISN 10). Presented at the Collegium Internationale Neuro-psychopharmacolegium 25th Biennial Congress, Chicago, Illinois, 9-13 July 2006
4. Eriksson, L., Almqvist, A., Mehnert, A., Ingham, M., Eriksson, B.: Reduction in need for institutional care in chronic schizophrenia subjects switched to long-acting risperidone. Presented at the 42nd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 7-11 December 2003
5. Eriksson, L., Almqvist, A., Mehnert, A., Ingham, M., Eriksson, B.: Treatment with long acting risperidone significantly reduces the need for institutional psychiatric care regardless of previous treatment. Presented at the 45th Annual and 4th Mediterranean Meeting of the Scandinavian College of Neuro-psychopharmacology, Juan-les-Pins, France, 21-24 April 2004
6. Södra Regionsvårdsnämnden. 2006 price list for the University Hospital in Malmö, Region Skåne (2006)
7. Samverkansnämnden Västra Sjukvårdsregionen. Utomlänspriser 2006 För vårdtjänster enligt samverkansavtal om hälso-och sjukvård inom Västra sjukvårdsregionen. Västra Götalandsregionen (2006)
8. FASS (Swedish Drug Price List), The Swedish Association of the Pharmaceutical Industry (2006)
9. A Taylor A Currie K Lloyd M Price K Peperell 2008 Impact of risperidone long acting injection on resource utilization in psychiatric secondary care J. Psychopharmacol. 22 128 131 10.1177/0269881107084068 (Pubitemid 351322859)
10. F Gianfrancesco R-H Wang R Mahmoud R White 2002 Methods for claims-based pharmacoeconomic studies in psychosis Pharmacoeconomics 20 499 511 10.2165/00019053-200220080-00001